Filing Details

Accession Number:
0000914190-19-000460
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-12-06 16:50:56
Reporting Period:
2019-12-04
Accepted Time:
2019-12-06 16:50:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
842023 Bio-Techne Corp TECH Biological Products, (No Disgnostic Substances) (2836) 411427402
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1197788 J Harold Wiens 614 Mckinley Place Ne
Minneapolis MN 55413
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-12-04 2,000 $87.83 7,221 No 4 M Direct
Common Stock Disposition 2019-12-04 485 $216.47 6,736 No 4 S Direct
Common Stock Disposition 2019-12-04 514 $217.29 6,222 No 4 S Direct
Common Stock Disposition 2019-12-04 921 $218.75 5,301 No 4 S Direct
Common Stock Disposition 2019-12-04 80 $219.31 5,221 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2019-12-04 2,000 $0.00 2,000 $87.83
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2014-05-15 2024-05-15 No 4 M Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Option (right to buy) $91.78 2014-10-30 2024-10-30 4,000 4,000 Direct
Common Stock Stock Option (right to buy) $87.34 2016-10-29 2025-10-28 4,260 4,260 Direct
Common Stock Stock Option (right to buy) $101.19 2017-10-26 2026-10-26 3,985 3,985 Direct
Common Stock Stock Option (right to buy) $125.05 2018-10-25 2027-10-26 3,125 3,125 Direct
Common Stock Stock Option (right to buy) $179.84 2019-10-24 2028-10-25 1,898 1,898 Direct
Common Stock Stock Option (right to buy) $201.64 2029-10-24 2,011 2,011 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2024-10-30 4,000 4,000 Direct
2025-10-28 4,260 4,260 Direct
2026-10-26 3,985 3,985 Direct
2027-10-26 3,125 3,125 Direct
2028-10-25 1,898 1,898 Direct
2029-10-24 2,011 2,011 Direct
Footnotes
  1. The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2019.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.00 to $216.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.21 to $217.54, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.28 to $218.96, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.31 to $219.32, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.